SCHEMBL26075965

SCHEMBL26075965

CCCCCCCCCOc1ccc(-c2ccc(-c3cc(C)c4cc(F)ccc4n3)cc2F)cc1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 2/20 0.44
▸ PLA2G2A P14555 3/20 0.42
▸ PTPN11 Q06124 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ DHODH Q02127 4/20 0.39
▸ KCNH2 Q12809 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PDE10A Q9Y233 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075283 1.00 PDE2A (0.44) PDE2APLA2G2APTPN11MAPTDHODH
SCHEMBL26075247 1.00 PDE2A (0.44) PDE2APLA2G2APTPN11MAPTDHODH
SCHEMBL26075280 1.00 PDE2A (0.44) PDE2APLA2G2APTPN11MAPTDHODH
SCHEMBL26075277 0.99 PLA2G2A (0.42) PDE2APLA2G2APTPN11MAPTDHODH
SCHEMBL26075237 0.97 PLA2G2A (0.44) PDE2APLA2G2AMAPTDHODHKCNH2
SCHEMBL26075234 0.93 DHODH (0.44) PLA2G2ADHODHPDE10A
SCHEMBL26075868 0.90 PLA2G2A (0.41) PDE2APLA2G2APTPN11MAPTDHODH
SCHEMBL26075878 0.90 PLA2G2A (0.41) PDE2APLA2G2APTPN11MAPTDHODH
SCHEMBL26075880 0.90 PLA2G2A (0.41) PDE2APLA2G2APTPN11MAPTDHODH
SCHEMBL26074014 0.90 PLA2G2A (0.48) PDE2APLA2G2AMAPTDHODHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD PDE2A 2223/4885PLA2G2A 1679/4885PTPN11 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback